Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2015—Illumina has launched TruSight Tumor 15, a next-generation sequencing panel designed to identify sequence variants in 15 genes commonly associated with marketed therapeutics. The sequencing panel is optimized for damaged and degraded formalin-fixed, paraffin-embedded tumor samples, enabling low frequency somatic variant detection from limited nucleic acid inputs.
November 2015—Maine Standards released its Validate SP2 calibration verification/linearity test kit, which evaluates albumin, C-reactive protein, haptoglobin, and prealbumin in a human-serum–based matrix.
November 2015—Biocare Medical announced the availability of CK HMW + p63 + AMACR (RM) as an in vitro diagnostic double stain for multiplex immunohistochemistry. This patented antibody cocktail may be useful in the evaluation of normal prostate glands, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
November 2015—Adaptive Biotechnologies announced a publication in Science Translational Medicine on a novel technology for pairing T-cell receptor alpha and beta chain sequences at high throughput.
November 2015—Mindray received 510(k) clearance to market and sell the Mindray BC-3600 Auto Hematology Analyzer, which aims to meet the testing needs of small and mid-volume hematology laboratories. The BC-3600 Hematology Analyzer features closed-tube sampling via a single push button.
November 2015—Thermo Fisher Scientific received the in vitro diagnostics device CE mark for its Thermo Scientific Prelude MD HPLC, Endura MD mass spectrometer, and ClinQuan MD software.
November 2015—Clarient Diagnostics will offer the FDA-approved PD-L1 companion diagnostic, which will help identify patients most likely to benefit from Merck’s lung cancer drug Keytruda.
November 2015—Streck has acquired Fertility Solutions’ sperm count and post-vasectomy quality control products. The sperm count controls for fertility diagnosis have been renamed Sperm-Chex and Sperm-Chex Post VC.
Lab Sensor Solutions will partner with MarketLab to distribute T-Tracks, which tracks, in real time, the temperature and location of clinical samples in transit, preventing laboratory specimen spoilage and loss and ensuring regulatory compliance. T-Tracks data are delivered to lab personnel’s desktops, laptops, and mobile devices.
QuanDx announced that its Leukemia Fusion Genes (Q30) Screening Kit has been released as a CE IVD product. The Leukemia Fusion Genes (Q30) product is a qualitative in vitro diagnostic kit for use in a clinical laboratory for the simultaneous detection of 30 fusion genes using a novel multiplex reverse transcription real-time PCR system.
